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Abstract  
Background 
There are many methods for analyzing microarray data that group together genes 
having similar patterns of expression over all conditions tested.  However, in many 
instances the biologically important goal is to identify relatively small sets of genes 
that share coherent expression across only some conditions, rather than all or most 
conditions as required in traditional clustering; e.g. genes that are highly up-regulated 
and/or down-regulated similarly across only a subset of conditions.  Equally important 
is the need to learn which conditions are the decisive ones in forming such gene sets 
of interest, and how they relate to diverse conditional covariates, such as disease 
diagnosis or prognosis. 
Results 
We present a method for automatically identifying such candidate sets of biologically 
relevant genes using a combination of principal components analysis and information 
theoretic metrics.  To enable easy use of our methods, we have developed a data 
analysis package that facilitates visualization and subsequent data mining of the 
independent sources of significant variation present in gene microarray expression 
datasets (or in any other similarly structured high-dimensional dataset).  We applied 
these tools to two public datasets, and highlight sets of genes most affected by 
specific subsets of conditions (e.g. tissues, treatments, samples, etc.).  Statistically 
significant associations for highlighted gene sets were shown via global analysis for 
Gene Ontology term enrichment.  Together with covariate associations, the tool 
provides a basis for building testable hypotheses about the biological or experimental 
causes of observed variation. 
Conclusion 
We provide an unsupervised data mining technique for diverse microarray expression 
datasets that is distinct from major methods now in routine use.  In test uses, this 
method, based on publicly available gene annotations, appears to identify numerous 
sets of biologically relevant genes.  It has proven especially valuable in instances 
where there are many diverse conditions (10’s to hundreds of different tissues or cell 
types), a situation in which many clustering and ordering algorithms become 
problematic.  This approach also shows promise in other topic domains such as multi-
spectral imaging datasets.  
Background  
Bioinformatics has placed much emphasis on using various unsupervised clustering 
techniques as a means to understand the information present in gene microarray 
expression datasets.  Clustering techniques produce a rich taxonomy of results by 
defining groups of genes that act more or less similarly across a number of 
experimental conditions. The diverse approaches to clustering genes by expression 
levels include k-means [1], self-organizing maps [2], hierarchical algorithms [3;4] and 
probabilistic models [5].  Some approaches permit clustering of the conditions as well 
[6;7;8].  Based on co-expression, genes that comprise individual expression clusters 
are often postulated to be co-regulated, and to the extent that this hypothesis is correct 
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in any specific biological situation, the gene cluster definitions can offer key insights 
into gene regulatory network (GRN) structure and function.  
 
Another common data mining task is to try to identify small sets of genes that can 
serve as effective predictors of disease diagnosis or prognosis.  While clustering at its 
best is good at finding sets of genes that are similarly expressed across all conditions 
within a dataset, many issues (e.g. selection of K, stochastic effects, and “noise” from 
large numbers of genes that change little over most of the conditions) can prevent 
clustering from successfully highlighting small groups of interestingly co-expressed 
genes [9;10].  This often encountered problem is addressed in part by hierarchical 
phylogenetic ordering algorithms such as average linkage in Mike Eisen’s cluster 
program [3], but the information biologists seek regarding shared sub-patterns of co-
expression can be obscured by both algorithmic and visualization constraints.  The 
algorithmic limitations in hierarchical clustering confound and “cover” the presence 
and organization of smaller and more specific gene groups that are similar across only 
a subset of conditions within the larger dataset.  In any case, biologists generally 
subjectively define a cluster of genes from such phylogenetic trees based largely on 
human pattern recognition.  Finally, nothing inherent in the clustering approach helps 
to direct a biologist to which cluster is interesting or relevant.  Instead, biologists 
generally take the path of focussing on a group of genes exhibiting a pattern of 
expression that supports a specific hypothesis, or search for a known gene or genes of 
interest within a cluster to form an explanation for others in the cluster.  
 
Support vector machines have been shown to be useful for identifying small sets of 
related and predictive genes [11;12;13;14], but represent a supervised learning 
approach which requires one to first define a set of known positive examples, a set of 
known negative examples, and a specific covariate to predict.  We wanted an 
unsupervised algorithm that would help us to find relationships and structure in the 
data that is more specific than what clustering algorithms usually deliver, yet is 
hypothesis independent.  We found it efficient and useful to use as an independent 
starting tool a very direct approach based on principal components analysis (PCA, see 
Methods section).  A virtue is that this approach is computationally efficient for very 
large datasets, especially compared with most clustering algorithms, but is also 
applicable to much smaller ones.  It allows one to directly explore each of the 
independent and diverse sources of variation present within a gene expression dataset 
and to subsequently identify the specific genes that vary the most, together with the 
conditions in which they vary.     
 
Unlike conventional clustering and ordering algorithms, this PCA based approach 
permits a gene to be highlighted and grouped as influential in multiple condition sets, 
whereas in cluster membership a gene is typically assigned to one unique cluster. The 
“single cluster assignment” quality of traditional clustering and ordering algorithms is 
problematical because it tends to hide commonality of expression that is restricted to a 
small, interesting, and often entirely unpredicted subgroups of tissues, cell types, 
treatments or other condition types.  This situation, perhaps because of inherent 
properties of gene network structure, will arise increasingly as the number and 
diversity of conditions represented in expression datasets increases.   
 
The clustering method of Barkai et al. [15;16] addresses this issue of multiple 
membership in a different way, by using randomly-selected gene sets to iteratively 
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search for and refine self-consistent groups.  Their approach, which is related to PCA 
through singular value decomposition (SVD), also permits genes to be assigned to 
multiple “expression modules.” In contrast to the method presented here, there is no 
provision for correlating modules with covariate data. 
 
The use of principal components analysis presented here differs from other recent 
applications in gene expression analysis.  PCA is most commonly used in as a means 
of dimensionality reduction prior to clustering [7;17] or prior to classification [18;19].  
It is also used to visualize or confirm clustering results [19;20;21].  In contrast, our 
use of PCA aims to find, then examine, and where possible, generate hypotheses to 
explain individual principal components.  In this manner, we build on the 
observations by Hilsenbeck [22] Raychaudhuri et. al. [23] who used PCA to gain 
insight into the underlying factors present in the Chu et. al. yeast sporulation 
experiments [24].  Wall et. al. [25] introduced a novel use of singular value 
decomposition (SVD) for gene expression analysis that identifies non-exclusive gene 
groups, and Selaru et. al. [26] illustrated the potential of PCA to detect molecular 
phenotypic bases that correspond to relevant clinical or biological features of human 
tumors.  Their approach identifies a subset of principal components that correlate well 
with known covariates. Here we introduce methods that extend beyond producing 
gene groups and observing a few principal components.  Our methods provide a path 
for systematically analyzing each principal component by identifying the genes most 
influential in defining a particular principal component and the conditions in which 
those influential genes vary significantly.  Finally, we describe methods which aim to 
explain each principal component’s observed variance in terms of the condition 
variables deemed most likely to be driving the variance.  We also introduce a software 
package that implements these methods.  These methods and our software package 
provide automated and objective way of doing what a biologist naturally tries to do 
through inspection and pattern recognition.  
 
Implementation 
We have developed a Python package to implement the PCA interpretation capability 
described in detail in the Methodology section.  This PCA analysis package has been 
added to CompClust developed previously [9,27].  The combined packages allow one 
to cluster, classify and visualize numeric datasets that have discrete or numeric 
annotations (referred to as labelings, or labelled datasets), and to compare labelings 
with confusion matrices and metrics such as normalized mutual information (NMI) 
[28].  This PCA analysis tool (including the complete results for the dataset analysis 
described in the Results section) has also been made accessible through the 
CompClustWeb web-based interface [29].  Our software makes use of data 
manipulation and graphical plotting using the matplotlib package [30], and the 
statistics are generated using the rPy package [31] and Gary Strangman’s Python stats 
package [32]. 
 
The web-based front-end permits users to get a complete report on the interpretation 
of each principal component, including interactive PCA projection plots with the 
principal component’s extreme genes (PCEGs) highlighted; ranked lists of the PCEGs 
with detailed annotations; interactive significance-ordered gene set trajectory plots 
that permit users to drill down to the individual gene level; similarly ordered 
condition reports ordered by expression difference and grouped by significance, 
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including covariate info (with significantly correlated covariates highlighted); and 
finally a report of any suggestive covariates that are well correlated with the 
significant column grouping, including the confusion matrices and/or plots of 
statistics scores to back up the conclusions.  All principal component analysis and 
results generation is implemented in a Python package so that analyses of large 
datasets can be executed in a batch mode rather than through the graphical interface.  
Further, the software that implements the CompClustWeb interface is provided within 
the CompClust package, so a software developer can create his or her own 
CompClustWeb server to review results of their PCA interpretation.  
Results  
Application to Microarray Expression Data, Case 1: GNF Human Data 
We obtained gene expression data from the Genomics Institute of the Novartis 
Research Foundation ("GNF") Gene Expression Database via their SymAtlas web site 
[33,34].  The dataset is a challenge for most clustering algorithms because it contains 
158 tissue samples hybridized to two Affymetrix microarray chips: U133A and 
GNF1H.  The dataset combines the measurements of these chips to provide a total of 
33,689 unique probe identities across the 158 tissue samples.  Expression data are 
signal intensities estimated by Affymetrix Microarray Suite v5.  For our analysis we 
used the log base 2 of the expression signal, and included data for all tissues and 
probes (noting that absent and present calls were not provided with the signal 
intensities). We applied our principal components analysis tool to generate 
interpretations for each of this dataset’s 158 principal components. 
 
As detailed in the Methodology section, for each principal component we identified a 
set of gene probes occupying the high and low extremes of that principal component’s 
axis (we refer to these as principal component extreme genes, or PCEGs).  One can 
adjust parameters to recover smaller and larger numbers of PCEGs per component by 
specifying either a likelihood threshold or an explicit number of PCEGs.  The PCEGs 
are those probes having the most highly weighted values for that principal component, 
selected because they stand out from the others, they influence the principal 
component’s direction, and thus they warrant further investigation.  We selected 
probes with likelihoods less than extremeThresh=0.00001, which yielded on average 
20 low and 20 high extreme genes per principal component, though the sets sizes do 
vary considerably (µ=18.9, σ=17.2).  Next we identified the tissues in which the high 
PCEGs showed significantly different expression than the low PCEGs.  Visualizations 
produced include scatter plots of the extreme genes in PCA sub-spaces (PC N-1vs. PC 
N), and extreme gene trajectories in original tissue order as well as with tissues 
ordered by decreasing difference of mean of high PCEGs and mean of low PCEGs.  
The latter trajectory plot emphasizes how the extreme genes for a principal 
component show a pattern of expression that imposes a partitioning of tissues.  It is 
left to human interpretation to examine the extreme genes and the tissue partitioning 
exposed by each principal component, and thus to build hypotheses that attach 
meaning to the sources of variation.  The percentage variance explained by the top 50 
principal components is provided in Table 1.  Example results for two illustrative 
principal components, PC7 and PC21, are shown in Figures 1 through 4 and in Tables 
2 through 5, and are discussed below.  The complete analysis results generated for 
PC7 are provided as an example in the supplemental files: [see Additional file 1], [see 
Additional file 2], [see Additional file 3], [see Additional file 4], [see Additional file 
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5], [see Additional file 6]. Our supplemental materials web site [35] contains the 
complete collection of PCA interpretation results generated for these dataset for all 
principal components, as well as results of a comparable analysis done at 
extremeThresh=0.001 which yielded larger PCEG sets. 
 
We addressed the question of biological and statistical significance of PCs and the 
sets of extreme genes identified.  Each set of high and low extreme genes from each 
principal component was tested for Gene Ontology (GO) statistical enrichment when 
compared to the human GO annotations from NCBI's loc2go dataset using the 
hypergeometric to calculate the p-value of each GO term.  Terms that were enriched 
for a particular PC at 1% significance threshold and that were still significant 
following a Bonferroni correction for multiple hypothesis testing as described in [36] 
are reported as enriched (see Table 6).  26 of the top 42 PCEG lists, derived using a 
stringent cut-off of 0.00001, produced significant GO enrichments; no PCEG sets 
beyond PC42 showed significant enrichment.  As discussed below, many of the 
significant results showed obvious biological coherence and relationships to the 
specific samples associated with the PC of origin.  This argues that PCs containing 
less than 1% of the total variation in this dataset are still relevant and point to coherent 
and important gene sets and their related samples.   
 
Relationships between extreme gene sets and the corresponding sets of driving 
samples could be discerned for many PCs.  The Methodology section presents a way 
to additionally correlate each principal component’s sample partitioning with any 
available sample covariates.  Although some human sample covariate information is 
provided in our test case, the GNF human expression dataset is not amenable to this 
additional layer of analysis because multiple subject’s RNA samples were pooled 
prior to amplification and array hybridization.  However, a second publicly available 
dataset with rich covariate information is presented below. 
Application to Microarray Expression Data, Case 2: Human Diabetes 
 
We acquired a Human diabetes expression dataset [37] from the Broad Institute 
Cancer Program dataset repository [38] along with the corresponding phenotype 
covariate data, and applied the filtering step as they described to produce a set 
containing 10,983 probes across 43 samples.  Tissue samples were skeletal muscle 
biopsies from 3 diagnosis groups: normal glucose tolerance (NGT, n=17); impaired 
glucose tolerance (IGT, n=8); and Type 2 diabetes mellitus (DM2, n=18).  We used 
our PCA interpretation software to perform an unsupervised analysis of the DM2 vs. 
NGT subset (as that subset is comparable to the previous published result).  As 
described in the Methodology section, PCEG sets were determined using an 
extremeThresh likelihood threshold of 0.001, which yielded about 50 high and 50 low 
extreme genes per principal component.  For each principal component N, samples 
were partitioned in to UPN, FLATN and DOWNN sample sets on the basis of PC-N 
extreme high and extreme low expression differences. The supplemental materials 
contain PCA interpretation results for all 35 principal components, as well as results 
of a comparable analysis done at extremeThresh=0.0001 which yielded smaller PCEG 
sets (see [35]). 
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This dataset contains more than 50 covariates, which provides the opportunity to 
interpret each principal component by searching for covariates that correlate well with 
expression patterns in the PCEG sets.  As described in the Methodology section, we 
asked if any of the covariate annotations are well correlated with the partitioning of 
samples into UPN, FLATN and DOWNN sets.  Covariate distributions were compared 
across different partitions (when sufficient data was available) and any significant 
trends identified were recorded (see Table 7).  For covariates identified as 
significantly correlated with a principal component’s sample partitioning, covariate 
distribution plots were generated to further investigate and evaluate the apparent 
relationship.  For example, Figure 5 illustrates that PC14’s UP14 , FLAT14 and 
DOWN14 sample partitions appear to be significantly related to two covariate 
measurements: Insulin_0 (sig=0.0010); and Type2b_(%) (sig= 0.0077).  The 
Pearson’s correlation between the mean expression for the PC14EG-high set and 
Insulin_0 and Type2b_(%) covariates are r=0.411 and r=0.467 respectively. 
Discussion 
This PCA-based data-mining tool highlights specific patterns of expression and 
associates them in a convenient way with the genes and samples responsible for those 
patterns. Some associations in the first few principal components (PCs) of the GNF 
set reflect major features in the data that are expected.  This includes the global high 
and low constitutive expression profiles of PC1 (67% of variance in the GNF dataset).  
A component similar to this is often the first or second PC in Affymetrix array 
datasets.  GNF PC3, in contrast, highlighted brain/neuronal tissues, which we 
expected in this dataset because there are many more samples from brain regions than 
from any other tissue, and there are thousands of genes that are expressed in a general 
brain pattern.  The GO enrichment analysis associated with PC3lowEGs confirmed 
this impression by identifying neurogenesis, central nervous system, and synaptic 
terms as significantly enriched for PC3EG (Table 6). 
 
We asked if principal components that account individually for small fractions of 
variation in the data are likely to be significant.  Conventional practice generally 
ignores principal components accounting for a few percent, or less, of total variation, 
on the assumption that such minor components are most likely dominated by noise.  
We believe this assumption, that all of the PC’s accounting for small fractions of data 
should be ignored because they are artefact, to be wrong in the context of our 
analysis.  We believe this, in part, because in our analysis we find many PCEGs for 
minor components are statistically enriched (Table 6).  Further, computational 
experiments using randomized data fail to produce any significant enrichments.  This 
GO enrichment analysis, it should be noted, tends to underestimate the fraction of 
gene sets that are significant. This is a known artefact in instances where the input 
gene number (here those passing the selected rank sum threshold) is small, and its 
effects are exacerbated by the fact that GO annotations for human are still very much 
in a building phase.  Many genes that will eventually be associated with GO terms are 
not yet entered.  This means that reducing the threshold modestly, and therefore 
increasing the gene number, can uncover additional significant GO term enrichment 
in some of these PCs.  For complete results of GNF analysis at p<=0.001 see our 
supplemental materials web site [35]. 
 
Viewed from a biological perspective, this PCA mining revealed several different 
classes of relationships. GNF PC21 is a good example of a component that highlights 
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a coherent gene set and its corresponding tissues, many of which would also be 
grouped together by conventional clustering algorithms.   This is true even though 
PC21 accounts for just 0.25% of total variation.   The PC21EG-low set (defined at 
p<=0.00001) was enriched in a statistically significant way for five different GO 
terms (Table 6), and these terms (myogenesis, muscle contraction, etc.) tell a simple 
and internally consistent story about muscle development and function.  The top 
tissue samples driving PC21-low are skeletal muscle, tongue (also composed largely 
of striated muscle), heart and thyroid (which includes a population of myoid cells).  
Most top-ranked genes in this PCEG set are so specific for striated muscle that they 
would also appear together in conventional clusterings, although many clustering 
approaches become technically problematic with datasets of this size. However the 
PC21EG-low list differs from a conventional muscle cluster because it also includes 
some genes that are partly associated with muscle and partly associated with other 
tissues. PP1R1A, a regulatory subunit of protein phosphatase1, is such a gene.  A role 
for it in striated muscle is suggested based on its coherent presence in tongue, skeletal 
and cardiac samples, even though it might well not have been seen in this light by 
standard clustering. 
 
The second example is GNF PC7, which accounts for 0.81% of variation.  It 
illustrates a different kind of biological relationship that more strongly distinguishes 
results of PCA mining from classical clustering.  Top extreme genes associated with 
PC7 by inspection turn out to be a “who’s who” of extracellular matrix components (a 
specific subset of fibronectins, collagens, laminins plus matrix associated proteins like 
MFAP5, MGP, LUM; regulatory molecules that mediate stability and function of 
those matrix components (thrombospondin, SPARC, ADAMTS1, Plod2); and matrix 
associated signalling and matrix associated signal modulators (insulin like growth 
factor binding proteins 7, 8 and 10; Sema3c).  GO analysis confirms what inspection 
of the top PC7EGs suggested: namely that a set of extracellular matrix components 
are expressed in these driving tissues.  It is instructive to look at the individual 
expression profiles for these genes directly at the GNF website and also in aggregate, 
as represented in the tissue (conditions) list in Table 2.  The most prominent 
contributing tissues associated with high expression of these genes are informative 
specifically because they do not constitute a group that would have been selected a 
priori as a coherent set based on known tissue function or shared developmental 
origin.    
 
This is useful because a biologist interrogating the GNF database would not likely 
have constructed a query combining adipocytes, smooth muscle, bronchial epithelium, 
nor would one expect traditional clustering algorithms to place these genes so close to 
each other as to catalyze the same observation. Similarly, conventional ordering 
algorithms would not have placed them adjacent to each other because other parts of 
their expression profiles, containing different genes than those in PC7, would 
dominate their positions.  And concerning genes, they have, in addition to 
commonalities of expression highlighted by PC7, differences from each other in 
additional diverse tissues not highlighted by PC7.  The PCA grouping gives impetus 
and a necessary starting gene list to search for one or more factors or regulatory 
RNAs with a similar expression pattern, or to search for a shared and perhaps 
evolutionarily conserved cis-acting DNA sequence motifs. It is unlikely that these 
working hypotheses would have been arrived at easily by widely used methods of 
gene expression analysis.  
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The diabetes dataset offered us an opportunity to add more value to principal 
component interpretations by searching for covariates that appear correlated at some 
significance level.  The relationships highlighted between covariates and principal 
components are suggestive, but not conclusive by themselves.  Rather, they provide 
hypotheses that a researcher may wish to further investigate.  While we have not 
delved deeply into this dataset, we believe that a number of the principal components 
are highlighting a number of meaningful sources of variation present.  It is not clear 
whether this set should exhibit the same proportion of meaningful principal 
components as the GNF dataset, as by design the NGT vs. GM2 dataset does not 
contain substantial diversity of samples.  Likewise, the selection of covariates was 
focused on a narrow set of measurements selected to be indicative of diabetes status, 
and so many covariates are redundant.  We anticipate this tool will be maximally 
useful in cases where datasets are rich in both sample complexity and diversity of 
covariates. 
Conclusions  
Results presented above show that this PCA-mining approach can guide a user to 
biologically significant observations that both complement and reinforce those from 
conventional clustering analysis.   The software package and web interface make this 
style of microarray analysis straightforward and accessible. 
  
We have applied this to four additional microarray datasets (as yet unpublished) and 
to one multi-spectral imaging dataset.  In each case we found the interpretations that 
the tool presented to be useful.  In general, it seems that the top few principal 
components identify very broad characteristics of the data.  Digging to the deeper 
components that comprise smaller but more particular substructure in the data leads to 
more subtle but often meaningful observations, many being complementary to 
standard clustering.  
 
With respect to the top few components, PC1 is usually the approximate diagonal 
through the sample/condition space, explaining the overall variation in absolute 
expression level. For some other datasets we have noticed that the top few PCs can 
also highlight effects of preprocessing normalization steps or global data quality 
issues.  This means they do not necessarily expose the most important biological 
variation.  Thus, in one microarray dataset not shown here, PC2 was found to be 
extremely well correlated with a measure of quality of samples, as reflected by the 
percent of Affymetrix probes called present.  Given this evidence of data quality 
effects comprising a major source of variation over the entire dataset, one might be 
motivated to remove the major offending conditions, and then repeat the PCA 
interpretation on the remaining conditions (columns).  The idea is that an independent 
source of variation might be obscured by more dominant signals or noise present in 
the data from the offending condition.   
 
Our experience thus far leads us to think that this PCA interpretation method will 
contribute to microarray expression analysis, as one part of a panel of methods that 
are sensitive to different features in a dataset, such as sample number, gene number, 
and distribution of variation across the samples. The PCA method should be 
especially useful for large, complex datasets that offer rich variation among many 
samples.  What is certain is that there are almost always multiple sources of variation 
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in a dataset and that in any specific study their nature and relative strength is 
informative, whether the origin is an easily-understood biologic one, a technical one, 
or a poorly-understood but nonetheless biologically pertinent one.  
 
We are continuing to explore ways to improve our methodology and software 
package.  We anticipate further advances will come with software infrastructure 
improvements to permit covariate analyses of both column (sample) covariates and 
row (gene) covariates.  The CompClust dataset labeling capability [27] allows a user 
to attach diverse and numerous labelings to rows or columns.  For example we can 
pull in additional row (gene probe) annotations such as Gene Ontology (GO) 
functional groups.  Beyond explicitly comparing the NMI significance of specific row 
partitionings for discrete covariates, we plan to add routines to CompClust to 
automatically indicate when a group of genes are found to be enriched in specific GO 
categories (as was done in our analyses above), and more generally to handle large, 
discrete, multi-valued distributions of values.  Our use of NMI treats discrete 
covariates as discrete random variables that can have at most a single value per 
condition, and so does not optimally address issue of multi-valued discrete random 
variables (e.g. GNF data has covariate "concomitant medications" with values like 
"aspirin", "tylenol", and "aspirin & tylenol").  We are considering more elaborate 
extensions of mutual information or alternatives that might be able to take further 
advantage of such multi-valued entries. 
Availability and requirements 
The PCA interpretation software is implemented as one component of the CompClust 
Python package [9,27], which is freely available for non-commercial use. The 
software capability is also accessible through the CompClustWeb web-based interface 
[29]. The software that implements the web application is also included within the 
CompClust software distribution. 
 
Project name: the PCA interpretation component of CompClust 
Project home page: http://woldlab.caltech.edu/compclust 
Operating system(s): platform independent (Windows, Linux, Mac OS X) 
Programming language: Python 
Other requirements: Python 2.3 or higher (and some free Python packages) 
License: MLX Public License 1.0  (non-commercial use allowed) 
Use by non-academics: licence needed 
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We recommend that interested researchers use the web-based application, 
CompClustWeb, from any platform to review the PCA interpretation results for the 
GNF human gene expression and Broad Institute human diabetes expression data sets.   
We have written a CompClust PCA interpretation tutorial that demonstrates how to 
use CompClust’s programming interface to generate PCA interpretations.  Following 
the tutorial requires that CompClust and its Python prerequisites be installed.  We 
created an easy-to-use CompClustShell installer for Windows that provides 
everything needed.  For other operating systems (e.g. Linux & OS X) we recommend 
that a software developer or system administrator help with the CompClust source 
code installation.  We are working to simplify installation and plan to provide user-
friendly installers for other operating systems in the near future.  
Methodology 
We have developed the following algorithm for identifying and analyzing multiple 
independent sources of variance present within multi-dimensional sample datasets, in 
particular those that are produced by gene microarray expression experiments.  The 
overall approach can be summarized as follows: 1) perform principal components 
analysis of the dataset; for each principal component: 2) identify the most extreme 
gene probes (those with the highest or lowest weighting) for that principal component; 
3) identify and group any conditions in which those extreme probes vary significantly; 
4) identify any condition covariates that correlate well with the condition grouping.   
By extending the interpretation of each principal component from extreme genes 
(rows) to ordered groups of significant conditions (columns) and further to identifying 
statistically significant correlations with column covariates, we attempt to make full 
use of the available data, in an objective and data-driven way, to analyze and provide 
meaningful interpretations of the diverse sources of variation present within the 
dataset. 
Determine the Principal Components of the Dataset 
Our dataset D consists of nc columns (e.g. tissue samples or conditions) and nr row 
vectors (e.g. gene probes), each row vector  where .  Such a dataset 
is usually represented as a two-dimensional matrix (where ).  The 
dataset may optionally have nk supplemental covariate annotations C associated with 
each row or column.  Each annotation Ck where   can be either discrete (e.g. 
sex) or continuous (e.g. age), to permit the association of one discrete value per 
column (e.g. values male or female), or one continuous value per column (e.g. values 
12, 16, or 42). 
 
Our procedure starts by employing principal components analysis (PCA) to 
sequentially identify a series of new basis vectors or axes 
 
in the 
high-dimensional column space that are each aligned sequentially to capture the 
most as-yet unexplained variance.  This is accomplished by applying the numeric 
procedure singular value decomposition (SVD) to the covariance matrix of D, cov(D), 
to produce the decomposition  that contains the eigenvectors of cov(D) 
in the columns of U and eigenvalues in the diagonal of S such that the eigenvalues are 
sorted by descending size.  Each covariance eigenvector, or principal component 
, explains a fraction of the total variance contained in the dataset, 
and each principal component PCn+1 is orthogonal to the previous principal 
component PCn. such that they define the basis of a new vector space P.  These results 
are made available to the users in the form of nc plots, one for each of the principal 
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component vectors, as well as a plot of the singular values contained in the diagonal 
of S to indicate the relative amount of variance each component explains. 
Identify Extreme Gene Probes for each Principal Component 
Next, we project each data point  (corresponding to a gene probe, or row vector) 
into the new coordinate system by , effectively rotating the entire data 
point set D into the new principal component axes space, producing the rotated data 
set P.  Each data point in the rows of P corresponding to  has a coordinate for 
each principal component axis that describes where the data point  lies when 
projected along each axis .  For each principal component PCn 
( ) we select a set of data points from each end of that principal component 
axis- these are the extreme points for PCn, called the principal component extreme 
genes, or PCEGs for convenience.  The PCEGs can be identified and ranked in one of 
two ways: by identifying points having a low probability (p<=extremeThresh) of 
belonging to a Gaussian fit to the distribution of points along the PCn axis, or by 
taking a fixed number of nExtreme points at each tail of the distribution.  Hn is the 
resulting set of data points having the highest coordinate values for PCn, and Ln is the 
resulting set of data points having the lowest coordinate values for PCn.  These high 
and low extreme gene point sets are informative in and of themselves because they 
represent the most extreme of the data points along a principal axis of variation.  As 
such, the high and low PCEG sets are some of the primary outputs generated by our 
procedure.  We use the term “extreme” in a very general sense, in that the points stand 
out because they are far from the main distribution.  We do not mean to imply that 
such points are either biologically relevant or nuisance data that should be removed; 
rather we are interested in these points in an unbiased way.  By further analyzing their 
pattern of expression in the original axes we hope to gain a better understanding of 
their possible biologic significance.   
Identify Significant Conditions for each Principal Component 
The extreme gene points comprising Hn are located near one edge of the high-
dimensional cloud of points, and points Ln are near the opposite edge.  Thus, points Hn 
are likely to have coordinate values that are maximally different from points Ln in a 
subset of the original column space coordinate system.  Our procedure next seeks to 
identify in which of the original columns (the original axes or dimensions) we find the 
greatest difference of values for points Hn versus points Ln.  We do this by comparing 
distributions of values in Hnj versus Lnj for each of the original columns j ( ).  
A two-sided Wilcoxon rank sum test is used to estimate the likelihood that these two 
sets of values are drawn from the same distribution [39]; the resulting p-values for 
each column are used to rank order and group the columns, rather than as actual 
probabilities. Columns having a likelihood less than a user-defined significance level 
test1Thresh are identified and placed into one of two column sets: UPn for those 
where column j has mean(Hnj ) > mean(Lnj), and DOWNn for those columns j where 
mean(Hnj ) < mean(Lnj).  Remaining columns that do not show significant variation 
are placed in the column set FLATn.  The column sets are also meaningful outputs of 
our procedure, as UPn and DOWNn describe the groups of columns in which the 
extreme genes Hn and Ln vary significantly.  Our procedure can output these columns 
and column sets in various orders simply as an aid to human interpretation, including: 
original column order; grouped by set and within set ordered by the Wilcoxon p-value 
significance; ordered by mean difference, mean(Hnj ) - mean(Lnj); or ordered by the 
eigenvector column loading.  Taken together, the PCEG point sets and significant 
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column sets should provide valuable insight to researchers wishing to interpret each of 
the sources of variation identified by the principal components procedure. 
Interpret Each Principal Component Using Covariate Annotations 
When provided additional covariate annotations C, the procedure seeks to determine 
which, if any of the annotations Ck are well correlated with the partitioning of 
columns into the sets {UPn , FLATn , DOWNn}.  A discrete annotation Ck containing 
m unique values V1, V2, … Vm also defines a partitioning of the columns { KV1 , KV2 , 
…, KVm } where KV1 is the set of columns that share the value V1, KV2 are those that 
share value V2, and so on.  An information theoretic measure known as normalized 
mutual information (NMI) [28] describes the degree to which two discrete random 
variables share information. When there is high mutual information, knowing the 
value of one of the variables should be useful predictor of the other variable. (See [9] 
for a description of the merits of NMI in terms of clustering and understanding the 
relationships between clusterings.) We construct the 3 x m confusion matrix to 
compare the {UPn , FLATn , DOWNn} column partitioning with the { KV1 , KV2 , …, 
KVm } partitioning and calculate an NMI score between the partitionings.  Because the 
usual NMI score is not symmetric (i.e. NMI(r,c) ≠ NMI(c,r) ), we use a variant that 
we refer to as the average NMI score, which is simply the average of the NMI of the 
confusion matrix and the NMI of the transpose of the confusion matrix. Those 
covariates Ck having an average NMI greater than a user defined threshold nmiThresh 
are added to the set of significant covariate annotations An.   
 
We apply a different approach when evaluating the Ck that are continuous covariates.  
We need to assess whether each principal component’s {UPn , FLATn , DOWNn} 
column partitioning correlates with each Ck distribution of values.  We can separately 
score three different partitioning schemes, UPn vs. DOWNn , {UPn+FLATn} vs. 
DOWNn , and UPn vs.{FLATn+DOWNn}, by determining if Ck ’s value distributions 
differ significantly across the partition.  E.g. does Ck within UPn have a different 
distribution than Ck within DOWNn?  Next, does Ck within {UPn + FLATn} have a 
different distribution than Ck within DOWNn?  Finally, does Ck within UPn have a 
different distribution than Ck within{FLATn+DOWNn}?  For each partition scheme we 
again use a two-tailed Wilcoxon rank sum test, including the small sample 
adjustments when sample size is less than 10, to determine whether the covariate’s 
value distributions on each side of the partitioning differ significantly from each 
other.  A minSetSize parameter can be specified as desired to reduce false positives 
when set sizes are very small, e.g. when comparing a distribution of 2 values vs. 7 
values. Thus we calculate the Wilcoxon p-value for three partitionings of columns: 
UPn vs. DOWNn , {UPn+FLATn} vs. DOWNn , and UPn vs.{FLATn+DOWNn}.  Those 
covariates having a p-value less than the user defined threshold test2Thresh for any of 
the three partitionings are added to the set of significant covariate annotations An.   
 
Upon completion of the covariate analysis, covariates in the set An, that previously 
met user-controlled significance thresholds are reported by the software.  Covariate 
reports provide the following information: For discrete-valued covariates, 
corresponding confusion matrices and average NMI scores are reported; for 
continuous-valued covariates, the three Wilcoxon p-values are reported together with 
supporting plots illustrating the covariate distributions.   There is no guarantee that 
any covariates will be significantly related to a principal component.  Conversely, 
spurious relationships might be reported, especially in the case of small numbers of 
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samples due to small column partitions.  The tool simply points to those covariates 
related to a principal component that also satisfy a user-controlled significance 
threshold.  It is up to the investigator to consider these hypotheses and to confirm the 
interesting ones through further investigation.  
Terminating Condition 
We have shown that some large-scale expression datasets have biologically pertinent 
structure that is revealed by deep PC analysis that goes well beyond the first few 
principal components.  However there are limits to the depth of mining and these 
limits depend on both size and character of the dataset.  In all cases, the last principal 
component is not free to seek a source of variation because it must be orthogonal to 
all prior nc-1 components.  To some degree that is also true of some portion of latter 
principal components that explain ever-diminishing fractions of the variance.  We 
suggest that a natural terminating condition exists: When a principal component 
cannot find any columns in which the extreme gene sets show significant differences, 
there is no need to proceed to subsequent principal components.  We observe that this 
condition is often not met because the extreme genes are typically differentially 
expressed in at least a few of the original columns (the original axes or dimensions), 
even for the most minor principal components.  We also observe that variants of a 
dataset (e.g. representative column subsets) can affect the relative ordering, but not 
the existence, of multiple factors or sources of variation that are reflected in the minor 
principal component regime.  We may therefore choose to investigate all principal 
components, but do so with the expectation that minor principal components will 
describe increasingly subtle sources of variation, which can, and often do, include 
noisy processes inherent in the data source. 
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Figures 
Figure 1  - GNF PC7 High and Low Extreme Gene Probes 
Scatter plot of N=33689 probe expression levels projected onto PC6 vs. PC7 space 
with high and low extreme gene sets H7 (red points, n=88) and L7 (blue points, n=20); 
extreme genes selected at extremeThresh=0.00001.  The extreme genes in H7 are 
listed in Table 2. 
 
 
Figure 2  - GNF PC7 Extreme Gene Trajectory Plot with Tissues Ordered by 
Significance 
Trajectory plots for high and low extreme gene sets H7 (red, n=88) and L7 (blue, 
n=20) with tissues ordered by decreasing mean(H7) - mean(L7), and thus grouped by 
significance (UP7 group at left, FLAT7 group in middle and LOW7 group at right) at 
test1Thresh=0.05.  Table 3 lists the tissues within UP7 and DOWN7 that occur at each 
end of this plot. 
 
 
Figure 3  - GNF PC21 High and Low Extreme Gene Probes 
Scatter plot of N=33689 probe expression levels projected onto PC20 vs. PC21 space 
with high and low extreme gene sets H21 (red points, n=37) and L21 (blue points, 
n=49); extreme genes selected at extremeThresh=0.00001. The extreme genes in L21 
are listed in Table 4. 
 
 
Figure 4  - GNF PC21 Extreme Gene Trajectory Plot with Tissues Ordered by 
Significance 
Trajectory plots for high and low extreme gene sets H21 (red, n=37) and L21 (blue, 
n=49) with tissues ordered by decreasing mean(H21) - mean(L21), and thus grouped by 
significance (UP21 group at left, FLAT21 group in middle and LOW21 group at right) at 
test1Thresh=0.05. Table 5 lists the tissues within UP21 and DOWN21 that occur at 
each end of this plot. 
 
 
Figure 5  - Diabetes PC14 Sample Partitioning is Correlated with Certain 
Covariates 
When sufficient covariate data is available (a number of the measurements are 
missing for certain covariates), covariate distributions are compared across partitions 
and significant differences are reported (as in Table 7). When a covariate is identified 
as significantly correlated with a principal component’s sample partitioning, covariate 
distribution plots can be generated to further investigate and evaluate the apparent 
relationship.  For example, the diabetes dataset’s PC14 extreme genes partition the 
samples into UP14 (n=8), FLAT14 (n=17) and DOWN14 (n=10) based on their 
expression patterns. PC14’s UP14 vs. {FLAT14+DOWN14} sample partitioning appears 
related to the Insulin_0 measure (sig=0.001), and the {UP14+FLAT14} vs. DOWN14 
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partitioning appears related to Type2b_(%) (sig=0.008).  The mean expression of the 
PC14EG-high genes appears modestly correlated with Insulin_0 (r=0.411) and with 
Type2b_(%) (r=0.467). UP14 samples are in red, FLAT14 are black, and DOWN14 are 
blue. 
 
 - 20 - 
Tables 
Table 1 - Variance Explained by Principal Components 
Table 1 lists the percentage of variance in the GNF human tissue microarray data 
explained by each principal component.  The first 10 components explain 80.36% of 
the total variance.  Principal components 11 through 158 each explain less than 0.5% 
of the total variance, but combined explain almost 20%.   
Principal Component Percentage of Variance 
1 67.62 
2 4.66 
3 2.04 
4 1.41 
5 1.07 
6 0.90 
7 0.81 
8 0.69 
9 0.63 
10 0.54 
11 0.46 
12 0.42 
13 0.37 
14 0.35 
15 0.32 
16 0.31 
17 0.30 
18 0.29 
19 0.26 
20 0.26 
21 0.25 
22 0.24 
23 0.23 
24 0.22 
25 0.22 
26 0.22 
27 0.21 
28 0.20 
29 0.20 
30 0.19 
31 0.19 
32 0.19 
33 0.18 
34 0.18 
35 0.18 
36 0.18 
37 0.17 
38 0.16 
39 0.16 
40 0.16 
41 0.16 
42 0.16 
43 0.16 
44 0.15 
45 0.15 
46 0.15 
47 0.15 
48 0.15 
49 0.14 
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50 0.14 
Table 2 - PC7 High Extreme Genes 
Detailed info for (n=88) extreme genes in PC7 set H7, ordered most extreme first, 
including common name, description, and associated Gene Ontology terms (provided 
with the GNF dataset).  These extreme genes are shown as red points in Figure 1. 
PC-7 
Value 
Name Description Function 
18.63 COL1A2 collagen, type I, alpha 2 (GO:0005202) collagen; 
(GO:0005201) extracellular matrix 
structural constituent; 
(GO:0006817) phosphate transport; 
(GO:0001501) skeletal development; 
(GO:0008147) structural constituent of 
bone; 
17.89 LUM lumican (GO:0005518) collagen binding; 
(GO:0030199) collagen fibril organization; 
(GO:0005207) extracellular matrix 
glycoprotein; 
(GO:0005201) extracellular matrix 
structural constituent; 
(GO:0005203) proteoglycan; 
(GO:0007601) visual perception; 
15.48 TPM2 tropomyosin 2 (beta) (GO:0003779) actin binding; 
(GO:0007517) muscle development; 
(GO:0008307) structural constituent of 
muscle; 
15.30 IGFBP7 insulin-like growth factor 
binding protein 7 
(GO:0005520) insulin-like growth factor 
binding; 
(GO:0008285) negative regulation of cell 
proliferation; 
(GO:0001558) regulation of cell growth; 
14.54 CAV1 caveolin 1, caveolae 
protein, 22kDa 
(GO:0005198) structural molecule 
activity; 
(GO:0008181) tumor suppressor; 
14.08 COL3A1 collagen, type III, alpha 1 
(Ehlers-Danlos syndrome 
type IV, autosomal 
dominant) 
(GO:0008015) circulation; 
(GO:0005202) collagen; 
(GO:0005201) extracellular matrix 
structural constituent; 
(GO:0007397) histogenesis and 
organogenesis; 
(GO:0009887) organogenesis; 
(GO:0006817) phosphate transport; 
13.84 KCTD12 potassium channel 
tetramerisation domain 
containing 12 
(GO:0006813) potassium ion transport; 
(GO:0005515) protein binding; 
(GO:0005249) voltage-gated potassium 
channel activity; 
13.83 COL1A1 collagen, type I, alpha 1 (GO:0005202) collagen; 
(GO:0005201) extracellular matrix 
structural constituent; 
(GO:0007605) perception of sound; 
(GO:0006817) phosphate transport; 
(GO:0001501) skeletal development; 
(GO:0008147) structural constituent of 
bone; 
13.71 MGP matrix Gla protein (GO:0005509) calcium ion binding; 
(GO:0005201) extracellular matrix 
structural constituent; 
(GO:0007048)  oncogenesis; 
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(GO:0007605) perception of sound; 
(GO:0008147) structural constituent of 
bone; 
13.57 COL3A1 collagen, type III, alpha 1 
(Ehlers-Danlos syndrome 
type IV, autosomal 
dominant) 
(GO:0008015) circulation; 
(GO:0005202) collagen; 
(GO:0005201) extracellular matrix 
structural constituent; 
(GO:0007397) histogenesis and 
organogenesis; 
(GO:0009887) organogenesis; 
(GO:0006817) phosphate transport; 
13.25 CALD1 caldesmon 1 (GO:0003779) actin binding;  
(GO:0005516) calmodulin binding; 
(GO:0006936) muscle contraction; 
(GO:0007517) muscle development; 
(GO:0017022) myosin binding; 
(GO:0005523) tropomyosin binding 
13.19 MYL9 myosin, light polypeptide 
9, regulatory 
(GO:0005509) calcium ion binding; 
(GO:0008307) structural constituent of 
muscle 
13.12 FN1 fibronectin 1 (GO:0006953) acute-phase response; 
(GO:0007155) cell adhesion; 
(GO:0016477) cell migration; 
(GO:0005518) collagen binding; 
(GO:0005201) extracellular matrix 
structural constituent; 
(GO:0008201) heparin binding; 
(GO:0009611) response to wounding 
12.71 PLK2 polo-like kinase 2 
(Drosophila) 
(GO:0005524) ATP binding; 
(GO:0043123) positive regulation of I-
kappaB kinase/NF-kappaB cascade; 
(GO:0006468) protein amino acid 
phosphorylation; 
(GO:0004674) protein serine/threonine 
kinase activity; 
(GO:0004871) signal transducer activity; 
(GO:0016740) transferase activity 
12.59 CALD1 caldesmon 1 (GO:0003779) actin binding; 
(GO:0005516) calmodulin binding; 
(GO:0006936) muscle contraction; 
(GO:0007517) muscle development; 
(GO:0017022) myosin binding; 
(GO:0005523) tropomyosin binding 
12.54 CTGF connective tissue growth 
factor 
(GO:0006259) DNA metabolism; 
(GO:0007155) cell adhesion; 
(GO:0005194) cell adhesion molecule 
activity; 
(GO:0008151) cell growth and/or 
maintenance; 
(GO:0006928) cell motility; 
(GO:0008201) heparin binding; 
(GO:0005520) insulin-like growth factor 
binding; 
(GO:0005515) protein binding; 
(GO:0001558) regulation of cell growth; 
(GO:0009611) response to wounding 
12.39 D2S448 Melanoma associated gene (GO:0006955) immune response; 
(GO:0005152) interleukin-1 receptor 
antagonist activity; 
(GO:0004601) peroxidase activity 
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12.28 MFAP5 microfibrillar associated 
protein 5 
(GO:0005201) extracellular matrix 
structural constituent 
12.24 SEMA3C sema domain, 
immunoglobulin domain 
(Ig), short basic domain, 
secreted, (semaphorin) 3C 
(GO:0008151) cell growth and/or 
maintenance; 
(GO:0007275) development; 
(GO:0009315) drug resistance; 
(GO:0006955) immune response; 
(GO:0042493) response to drug 
12.20 ADAMTS1 a disintegrin-like and 
metalloprotease (reprolysin 
type) with thrombospondin 
type 1 motif, 1 
(GO:0008201) heparin binding; 
(GO:0016787) hydrolase activity; 
(GO:0005178) integrin binding; 
(GO:0007229) integrin-mediated signaling 
pathway; 
(GO:0004222) metalloendopeptidase 
activity; 
(GO:0008237) metallopeptidase activity; 
(GO:0008285) negative regulation of cell 
proliferation; 
(GO:0006508) proteolysis and 
peptidolysis; 
(GO:0008270) zinc ion binding 
11.99 SPARC secreted protein, acidic, 
cysteine-rich (osteonectin) 
(GO:0005509) calcium ion binding; 
(GO:0005518) collagen binding 
11.76 F3 coagulation factor III 
(thromboplastin, tissue 
factor) 
(GO:0007596) blood coagulation; 
(GO:0003801) blood coagulation factor 
activity; 
(GO:0004896) hematopoietin/interferon-
class (D200-domain) cytokine receptor 
activity; 
(GO:0006955) immune response; 
(GO:0004872) receptor activity; 
(GO:0004888) transmembrane receptor 
activity 
11.71 PLS3 plastin 3 (T isoform) (GO:0003779) actin binding; 
(GO:0005509) calcium ion binding 
11.70 THBS1 thrombospondin 1 (GO:0007596) blood coagulation; 
(GO:0005509) calcium ion binding; 
(GO:0007155) cell adhesion; 
(GO:0005194) cell adhesion molecule 
activity; 
(GO:0006928) cell motility; 
(GO:0007275) development; 
(GO:0004866) endopeptidase inhibitor 
activity; 
(GO:0008201) heparin binding; 
(GO:0007399) neurogenesis; 
(GO:0005515) protein binding; 
(GO:0004871) signal transducer activity; 
(GO:0005198) structural molecule activity 
11.69 PLOD2 procollagen-lysine, 2-
oxoglutarate 5-dioxygenase 
(lysine hydroxylase) 2 
(GO:0016491) oxidoreductase activity; 
(GO:0016702) oxidoreductase activity\, 
acting on single donors with incorporation 
of molecular oxygen\, incorporation of two 
atoms of oxygen; 
(GO:0008475) procollagen-lysine 5-
dioxygenase activity; 
(GO:0019538) protein metabolism; 
(GO:0006464) protein modification 
11.37 CAV1 caveolin 1, caveolae 
protein, 22kDa 
(GO:0005198) structural molecule 
activity; 
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(GO:0008181) tumor suppressor 
11.36 gnf1h04130_x_at None None 
11.28 FN1 fibronectin 1 (GO:0006953) acute-phase response; 
(GO:0007155) cell adhesion; 
(GO:0016477) cell migration; 
(GO:0005518) collagen binding; 
(GO:0005201) extracellular matrix 
structural constituent; 
(GO:0008201) heparin binding; 
(GO:0009611) response to wounding 
11.18 SMARCA1 SWI/SNF related, matrix 
associated, actin dependent 
regulator of chromatin, 
subfamily a, member 1 
(GO:0005524) ATP binding; 
(GO:0008026) ATP-dependent helicase 
activity; 
(GO:0003677) DNA binding; 
(GO:0004002) adenosinetriphosphatase; 
(GO:0006338) chromatin remodeling; 
(GO:0004386) helicase activity; 
(GO:0045182) translation regulator 
activity 
11.08 TAGLN transgelin (GO:0007517) Muscle development 
10.95 COL4A1 collagen, type IV, alpha 1 (GO:0003677) DNA binding; 
(GO:0005202) collagen; 
(GO:0005201) extracellular matrix 
structural constituent; 
(GO:0006817) phosphate transport 
10.90 CAV2 caveolin 2 (GO:0008181) tumor suppressor 
10.90 TPM1 tropomyosin 1 (alpha) (GO:0003779) actin binding; 
(GO:0007517) muscle development; 
(GO:0008016) regulation of heart rate; 
(GO:0005200) structural constituent of 
cytoskeleton; 
(GO:0008307) structural constituent of 
muscle 
10.85 GJA1 gap junction protein, alpha 
1, 43kDa (connexin 43) 
(GO:0007267) cell-cell signaling; 
(GO:0015285) connexon channel activity; 
(GO:0007507) heart development; 
(GO:0015075) ion transporter activity; 
(GO:0006936) muscle contraction; 
(GO:0007605) perception of sound; 
(GO:0043123) positive regulation of I-
kappaB kinase/NF-kappaB cascade; 
(GO:0004871) signal transducer activity; 
(GO:0006832) small molecule transport; 
(GO:0006810) transport 
10.82 COL1A2 collagen, type I, alpha 2 (GO:0005202) collagen; 
(GO:0005201) extracellular matrix 
structural constituent; 
(GO:0006817) phosphate transport; 
(GO:0001501) skeletal development; 
(GO:0008147) structural constituent of 
bone 
10.61 FXR1 fragile X mental 
retardation, autosomal 
homolog 1 
(GO:0003677) DNA binding; 
(GO:0003723) RNA binding; 
(GO:0006915) apoptosis; 
(GO:0003676) nucleic acid binding; 
(GO:0006913) nucleocytoplasmic 
transport 
10.60 COL6A3 collagen, type VI, alpha 3 cell adhesion (GO:0007155);cell adhesion 
molecule activity (GO:0005194);collagen 
(GO:0005202);extracellular matrix 
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structural constituent 
(GO:0005201);muscle development 
(GO:0007517);phosphate transport 
(GO:0006817);protein binding 
(GO:0005515);serine-type endopeptidase 
inhibitor activity (GO:0004867) 
10.52 CYR61 cysteine-rich, angiogenic 
inducer, 61 
cell adhesion (GO:0007155);cell 
proliferation (GO:0008283);chemotaxis 
(GO:0006935);embryogenesis and 
morphogenesis (GO:0007345);heparin 
binding (GO:0008201);insulin-like growth 
factor binding 
(GO:0005520);morphogenesis 
(GO:0009653);regulation of cell growth 
(GO:0001558) 
10.50 10-Sep septin 10 GTP binding (GO:0005525) 
10.44 IL1R1 interleukin 1 receptor, type 
I 
cell surface receptor linked signal 
transduction (GO:0007166);immune 
response (GO:0006955);inflammatory 
response (GO:0006954);interleukin-1 
receptor activity 
(GO:0004908);interleukin-1\, Type I\, 
activating receptor activity 
(GO:0004909);signal transducer activity 
(GO:0004871);transmembrane receptor 
activity (GO:0004888) 
10.37 WBP5 WW domain binding 
protein 1 
DNA binding (GO:0003677) 
10.35 LAMB1 laminin, beta 1 cell adhesion (GO:0007155);cell adhesion 
molecule activity (GO:0005194);protein 
binding (GO:0005515);structural molecule 
activity (GO:0005198) 
10.33 EMP1 epithelial membrane 
protein 1 
cell death (GO:0008219);cell growth 
(GO:0016049);cell proliferation 
(GO:0008283);development 
(GO:0007275);oncogenesis (GO:0007048) 
10.23 NRP1 neuropilin 1 axon guidance (GO:0007411);cell 
adhesion (GO:0007155);cell-cell signaling 
(GO:0007267);histogenesis and 
organogenesis 
(GO:0007397);neurogenesis 
(GO:0007399);organogenesis 
(GO:0009887);positive regulation of cell 
proliferation (GO:0008284);receptor 
activity (GO:0004872);signal transduction 
(GO:0007165);vascular endothelial growth 
factor receptor activity (GO:0005021) 
10.12 COL3A1 collagen, type III, alpha 1 
(Ehlers-Danlos syndrome 
type IV, autosomal 
dominant) 
circulation (GO:0008015);collagen 
(GO:0005202);extracellular matrix 
structural constituent 
(GO:0005201);histogenesis and 
organogenesis 
(GO:0007397);organogenesis 
(GO:0009887);phosphate transport 
(GO:0006817) 
10.10 CALD1 caldesmon 1 actin binding (GO:0003779);calmodulin 
binding (GO:0005516);muscle contraction 
(GO:0006936);muscle development 
(GO:0007517);myosin binding 
(GO:0017022);tropomyosin binding 
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(GO:0005523) 
10.10 THBS1 thrombospondin 1 blood coagulation (GO:0007596);calcium 
ion binding (GO:0005509);cell adhesion 
(GO:0007155);cell adhesion molecule 
activity (GO:0005194);cell motility 
(GO:0006928);development 
(GO:0007275);endopeptidase inhibitor 
activity (GO:0004866);heparin binding 
(GO:0008201);neurogenesis 
(GO:0007399);protein binding 
(GO:0005515);signal transducer activity 
(GO:0004871);structural molecule activity 
(GO:0005198) 
10.05 FN1 fibronectin 1 acute-phase response (GO:0006953);cell 
adhesion (GO:0007155);cell migration 
(GO:0016477);collagen binding 
(GO:0005518);extracellular matrix 
structural constituent 
(GO:0005201);heparin binding 
(GO:0008201);response to wounding 
(GO:0009611) 
10.03 SPARC secreted protein, acidic, 
cysteine-rich (osteonectin) 
calcium ion binding 
(GO:0005509);collagen binding 
(GO:0005518) 
10.02 IGFBP7 insulin-like growth factor 
binding protein 7 
insulin-like growth factor binding 
(GO:0005520);negative regulation of cell 
proliferation (GO:0008285);regulation of 
cell growth (GO:0001558) 
9.99 IL6ST interleukin 6 signal 
transducer (gp130, 
oncostatin M receptor) 
cell surface receptor linked signal 
transduction (GO:0007166);gp130 
(GO:0004898);immune response 
(GO:0006955);interleukin-6 receptor 
activity (GO:0004915);oncostatin-M 
receptor activity (GO:0004924);receptor 
activity (GO:0004872);signal transduction 
(GO:0007165) 
9.98 LAMB1 laminin, beta 1 cell adhesion (GO:0007155);cell adhesion 
molecule activity (GO:0005194);protein 
binding (GO:0005515);structural molecule 
activity (GO:0005198) 
9.94 TAZ transcriptional co-activator 
with PDZ-binding motif 
(TAZ) 
transcription coactivator activity 
(GO:0003713) 
9.93 DCN decorin chondroitin sulfate/dermatan sulfate 
proteoglycan (GO:0005205);histogenesis 
and organogenesis 
(GO:0007397);organogenesis 
(GO:0009887) 
9.93 ANXA1 annexin A1 calcium ion binding 
(GO:0005509);calcium-dependent 
phospholipid binding (GO:0005544);cell 
motility (GO:0006928);cell surface 
receptor linked signal transduction 
(GO:0007166);inflammatory response 
(GO:0006954);lipid metabolism 
(GO:0006629);phospholipase A2 inhibitor 
activity (GO:0019834);phospholipase 
inhibitor activity 
(GO:0004859);phospholipid binding 
(GO:0005543);receptor binding 
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(GO:0005102) 
9.89 MYH11 myosin, heavy polypeptide 
11, smooth muscle 
ATP binding (GO:0005524);actin binding 
(GO:0003779);calmodulin binding 
(GO:0005516);cell growth and/or 
maintenance (GO:0008151);motor activity 
(GO:0003774);muscle development 
(GO:0007517);protein amino acid 
alkylation (GO:0008213);striated muscle 
contraction (GO:0006941) 
9.89 EFEMP1 EGF-containing fibulin-like 
extracellular matrix protein 
1 
calcium ion binding (GO:0005509);visual 
perception (GO:0007601) 
9.88 SPUVE protease, serine, 23 chymotrypsin activity 
(GO:0004263);hydrolase activity 
(GO:0016787);proteolysis and peptidolysis 
(GO:0006508);trypsin activity 
(GO:0004295) 
9.87 Hs.514018 CDNA: FLJ22209 fis, 
clone HRC01496 
None 
9.80 FN1 fibronectin 1 acute-phase response (GO:0006953);cell 
adhesion (GO:0007155);cell migration 
(GO:0016477);collagen binding 
(GO:0005518);extracellular matrix 
structural constituent 
(GO:0005201);heparin binding 
(GO:0008201);response to wounding 
(GO:0009611) 
9.77 COL16A1 collagen, type XVI, alpha 1 cell adhesion (GO:0007155);collagen 
(GO:0005202);extracellular matrix 
structural constituent 
(GO:0005201);phosphate transport 
(GO:0006817);pregnancy (GO:0007565) 
9.73 SNX7 sorting nexin 7 intracellular protein transport 
(GO:0006886);intracellular signaling 
cascade (GO:0007242);protein transporter 
activity (GO:0008565) 
9.69 AHR aryl hydrocarbon receptor DNA binding (GO:0003677);apoptosis 
(GO:0006915);ligand-dependent nuclear 
receptor activity (GO:0004879);response 
to stress (GO:0006950);response to 
xenobiotic stimulus (GO:0009410);signal 
transduction (GO:0007165);transcription 
factor activity (GO:0003700);transcription 
from Pol II promoter (GO:0006366) 
9.57 COL6A1 collagen, type VI, alpha 1 DNA binding (GO:0003677);cell adhesion 
(GO:0007155);cell adhesion molecule 
activity (GO:0005194);collagen 
(GO:0005202);extracellular matrix 
structural constituent 
(GO:0005201);histogenesis and 
organogenesis 
(GO:0007397);molecular_function 
unknown (GO:0005554);phosphate 
transport (GO:0006817);protein binding 
(GO:0005515) 
9.55 KIAA0992 palladin amino acid metabolism (GO:0006520) 
9.54 COL5A2 collagen, type V, alpha 2 cell growth and/or maintenance 
(GO:0008151);collagen 
(GO:0005202);extracellular matrix 
glycoprotein (GO:0005207);extracellular 
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matrix structural constituent 
(GO:0005201);phosphate transport 
(GO:0006817) 
9.53 FBN1 fibrillin 1 (Marfan 
syndrome) 
calcium ion binding 
(GO:0005509);development 
(GO:0007275);extracellular matrix 
structural constituent 
(GO:0005201);skeletal development 
(GO:0001501);visual perception 
(GO:0007601) 
9.51 PAM peptidylglycine alpha-
amidating monooxygenase 
electron transporter activity 
(GO:0005489);monooxygenase activity 
(GO:0004497);peptide amidation 
(GO:0001519);peptidylglycine 
monooxygenase activity 
(GO:0004504);protein modification 
(GO:0006464) 
9.50 LOC92912 hypothetical protein 
LOC92912 
ligase activity (GO:0016874);ubiquitin 
conjugating enzyme activity 
(GO:0004840);ubiquitin cycle 
(GO:0006512);ubiquitin-protein ligase 
activity (GO:0004842) 
9.47 COL6A2 collagen, type VI, alpha 2 cell-cell adhesion (GO:0016337);collagen 
(GO:0005202);extracellular matrix 
organization and biogenesis 
(GO:0030198);extracellular matrix 
structural constituent 
(GO:0005201);muscle development 
(GO:0007517);phosphate transport 
(GO:0006817);protein binding, bridging 
(GO:0030674) 
9.45 PTX1 PTX1 protein None 
9.41 KIAA0992 palladin amino acid metabolism (GO:0006520) 
9.33 CSPG2 chondroitin sulfate 
proteoglycan 2 (versican) 
calcium ion binding (GO:0005509);cell 
adhesion (GO:0007155);chondroitin 
sulfate proteoglycan 
(GO:0005204);development 
(GO:0007275);glycosaminoglycan binding 
(GO:0005539);heterophilic cell adhesion 
(GO:0007157);hyaluronic acid binding 
(GO:0005540);lectin 
(GO:0005530);proteoglycan 
(GO:0005203);sugar binding 
(GO:0005529) 
9.32 CSPG2 chondroitin sulfate 
proteoglycan 2 (versican) 
calcium ion binding (GO:0005509);cell 
adhesion (GO:0007155);chondroitin 
sulfate proteoglycan 
(GO:0005204);development 
(GO:0007275);glycosaminoglycan binding 
(GO:0005539);heterophilic cell adhesion 
(GO:0007157);hyaluronic acid binding 
(GO:0005540);lectin 
(GO:0005530);proteoglycan 
(GO:0005203);sugar binding 
(GO:0005529) 
9.30 SERPINH1 serine (or cysteine) 
proteinase inhibitor, clade 
H (heat shock protein 47), 
member 1, (collagen 
binding protein 1) 
collagen binding (GO:0005518);heat 
shock protein activity 
(GO:0003773);response to stress 
(GO:0006950);serine-type endopeptidase 
inhibitor activity (GO:0004867);serpin 
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(GO:0004868) 
9.23 TM4SF6 transmembrane 4 
superfamily member 6 
cell adhesion molecule activity 
(GO:0005194);cell motility 
(GO:0006928);positive regulation of I-
kappaB kinase/NF-kappaB cascade 
(GO:0043123);signal transducer activity 
(GO:0004871) 
9.20 PTRF polymerase I and transcript 
release factor 
None 
9.19 LATS2 LATS, large tumor 
suppressor, homolog 2 
(Drosophila) 
ATP binding (GO:0005524);protein amino 
acid phosphorylation 
(GO:0006468);protein serine/threonine 
kinase activity (GO:0004674);transferase 
activity (GO:0016740);tumor suppressor 
(GO:0008181) 
9.12 CTBP2 C-terminal binding protein 
2 
L-serine biosynthesis 
(GO:0006564);negative regulation of cell 
proliferation 
(GO:0008285);oxidoreductase activity 
(GO:0016491);oxidoreductase activity, 
acting on the CH-OH group of donors, 
NAD or NADP as acceptor 
(GO:0016616);tumor suppressor 
(GO:0008181);viral replication 
(GO:0008166) 
9.06 ITGAV integrin, alpha V 
(vitronectin receptor, alpha 
polypeptide, antigen CD51) 
cell adhesion (GO:0007155);cell adhesion 
receptor activity (GO:0004895);cell-matrix 
adhesion (GO:0007160);integrin-mediated 
signaling pathway (GO:0007229);protein 
binding (GO:0005515) 
9.05 RCN2 reticulocalbin 2, EF-hand 
calcium binding domain 
calcium ion binding (GO:0005509);protein 
binding (GO:0005515);tumor suppressor 
(GO:0008181) 
8.98 CPD carboxypeptidase D carboxypeptidase A activity 
(GO:0004182);carboxypeptidase D 
activity (GO:0004187);carboxypeptidase 
activity (GO:0004180);hydrolase activity 
(GO:0016787);proteolysis and peptidolysis 
(GO:0006508);zinc ion binding 
(GO:0008270) 
8.98 FLJ21174 hypothetical protein 
FLJ21174 
None 
8.96 MGC5395 hypothetical protein 
MGC5395 
intracellular signaling cascade 
(GO:0007242);neurogenesis 
(GO:0007399);protein binding 
(GO:0005515) 
8.96 MFAP2 microfibrillar-associated 
protein 2 
extracellular matrix glycoprotein 
(GO:0005207);extracellular matrix 
structural constituent (GO:0005201) 
8.94 CRIM1 cysteine-rich motor neuron 
1 
cysteine-type endopeptidase activity 
(GO:0004197);insulin-like growth factor 
binding (GO:0005520);insulin-like growth 
factor receptor activity 
(GO:0005010);neurogenesis 
(GO:0007399);proteolysis and peptidolysis 
(GO:0006508);regulation of cell growth 
(GO:0001558);serine-type endopeptidase 
inhibitor activity (GO:0004867) 
8.92 ALDH1A3 aldehyde dehydrogenase 1 
family, member A3 
alcohol metabolism 
(GO:0006066);aldehyde dehydrogenase 
 - 30 - 
[NAD(P)+] activity 
(GO:0004030);aldehyde dehydrogenase 
activity (GO:0004028);lipid metabolism 
(GO:0006629);metabolism 
(GO:0008152);oxidoreductase activity 
(GO:0016491) 
8.92 MGC34132 hypothetical protein 
MGC34132 
None 
Table 3 - PC7 Tissue Partitioning and Ordering 
Partitioning and ordering of tissues into sets UP7 (n =51) and DOWN7 (n =48) sets 
found to have significant expression differences for H7 and L7 at test1Thresh=0.05.  
Tissues within groups are ordered by decreasing abs (mean(H7)-mean(L7)), which has 
the effect of placing the most significantly affected tissues at the top of each list.   The 
most significant tissues in UP7 are at the left of Figure 2, and the most significant 
conditions in DOWN7 are at the right of Figure 2. 
UP7 DOWN7 
SmoothMuscle PB-CD19+Bcells 
SmoothMuscle PB-CD19+Bcells 
CardiacMyocytes PB-BDCA4+Dentritic_Cells 
ADIPOCYTE PB-BDCA4+Dentritic_Cells 
ADIPOCYTE lymphomaburkittsRaji 
CardiacMyocytes lymphomaburkittsDaudi 
TestisGermCell lymphomaburkittsDaudi 
bronchialepithelialcells lymphomaburkittsRaji 
bronchialepithelialcells PB-CD56+NKCells 
PLACENTA bonemarrow 
PLACENTA bonemarrow 
TestisInterstitial PB-CD56+NKCells 
UterusCorpus leukemiapromyelocytic(hl60) 
Uterus 721_B_lymphoblasts 
fetalThyroid Tonsil 
OlfactoryBulb Tonsil 
TestisLeydigCell WHOLEBLOOD 
UterusCorpus 721_B_lymphoblasts 
fetalThyroid leukemiapromyelocytic(hl60) 
atrioventricularnode WHOLEBLOOD 
TestisInterstitial thymus 
TestisLeydigCell PB-CD8+Tcells 
TestisSeminiferousTubule PB-CD8+Tcells 
atrioventricularnode thymus 
DRG lymphnode 
fetallung Heart 
Uterus lymphnode 
ciliaryganglion PB-CD14+Monocytes 
TestisGermCell PB-CD4+Tcells 
AdrenalCortex PB-CD4+Tcells 
fetallung PB-CD14+Monocytes 
ciliaryganglion BM-CD71+EarlyErythroid 
DRG BM-CD34+ 
TONGUE Liver 
SuperiorCervicalGanglion Heart 
Ovary BM-CD71+EarlyErythroid 
TestisSeminiferousTubule BM-CD34+ 
skin BM-CD105+Endothelial 
OlfactoryBulb salivarygland 
TONGUE leukemialymphoblastic(molt4) 
Ovary Liver 
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TrigeminalGanglion Lung 
AdrenalCortex Lung 
PancreaticIslets leukemialymphoblastic(molt4) 
skin BM-CD105+Endothelial 
fetalbrain BM-CD33+Myeloid 
TrigeminalGanglion salivarygland 
fetalbrain BM-CD33+Myeloid 
Amygdala  
SuperiorCervicalGanglion  
PrefrontalCortex  
  
  
  
  
  
  
  
  
Table 4 – PC21 Low Extreme Genes 
Detailed info for (n=49) extreme genes in PC21 set L21, ordered most extreme first, 
including common name, description, and associated Gene Ontology terms (provided 
with the GNF dataset). These extreme genes are shown as blue points in Figure 3. 
PC-21 
Value 
Name Description Function 
-11.74 Ckm creatine kinase, muscle creatine kinase activity (GO:0004111); 
transferase activity, transferring 
phosphorus-containing groups 
(GO:0016772) 
-11.61 ACTA1 actin, alpha 1, skeletal 
muscle 
motor activity (GO:0003774);muscle 
contraction (GO:0006936);muscle 
development (GO:0007517);structural 
constituent of cytoskeleton 
(GO:0005200) 
-10.27 MYH7 myosin, heavy polypeptide 
7, cardiac muscle, beta 
ATP binding (GO:0005524);actin 
binding (GO:0003779);calmodulin 
binding (GO:0005516);microfilament 
motor activity (GO:0000146);motor 
activity (GO:0003774);muscle 
contraction (GO:0006936);muscle 
development (GO:0007517);protein 
amino acid alkylation 
(GO:0008213);striated muscle 
contraction (GO:0006941);structural 
constituent of muscle (GO:0008307) 
-10.01 TPM1 tropomyosin 1 (alpha) actin binding (GO:0003779);muscle 
development (GO:0007517);regulation 
of heart rate (GO:0008016);structural 
constituent of cytoskeleton 
(GO:0005200);structural constituent of 
muscle (GO:0008307) 
-9.10 MYL1 myosin, light polypeptide 
1, alkali; skeletal, fast 
calcium ion binding 
(GO:0005509);muscle development 
(GO:0007517);structural constituent of 
muscle (GO:0008307) 
-9.10 TNNC1 troponin C, slow calcium ion binding 
(GO:0005509);muscle development 
(GO:0007517) 
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-8.92 PPP1R1A protein phosphatase 1, 
regulatory (inhibitor) 
subunit 1A 
glycogen metabolism 
(GO:0005977);protein phosphatase 
inhibitor activity (GO:0004864);signal 
transduction (GO:0007165);type 1 
serine/threonine specific protein 
phosphatase inhibitor activity 
(GO:0004865) 
-8.79 TNNC2 troponin C2, fast calcium ion binding 
(GO:0005509);muscle development 
(GO:0007517) 
-8.71 TNNT1 troponin T1, skeletal, slow muscle development 
(GO:0007517);tropomyosin binding 
(GO:0005523) 
-8.70 KRT14 keratin 14 (epidermolysis 
bullosa simplex, Dowling-
Meara, Koebner) 
biological_process unknown 
(GO:0000004);structural constituent of 
cytoskeleton (GO:0005200);structural 
constituent of epidermis (GO:0030280) 
-8.67 TTID titin immunoglobulin 
domain protein (myotilin) 
muscle contraction 
(GO:0006936);protein binding- 
(GO:0005515);structural constituent of 
muscle (GO:0008307) 
-8.49 HUMMLC2B myosin light chain 2 calcium ion binding 
(GO:0005509);structural constituent of 
muscle (GO:0008307) 
-8.35 TRIM T-cell receptor interacting 
molecule 
DNA binding (GO:0003677);cellular 
defense response (GO:0006968);signal 
transduction 
(GO:0007165);transmembrane receptor 
protein tyrosine kinase adaptor protein 
activity (GO:0005068) 
-8.20 TTN titin ATP binding (GO:0005524);calmodulin 
binding (GO:0005516);cation 
transporter activity 
(GO:0008324);hematopoietin/interferon-
class (D200-domain) cytokine receptor 
activity (GO:0004896);muscle 
development (GO:0007517);myosin 
binding (GO:0017022);protein amino 
acid phosphorylation 
(GO:0006468);protein serine/threonine 
kinase activity (GO:0004674);regulation 
of actin filament length 
(GO:0030832);somatic muscle 
development (GO:0007525);striated 
muscle contraction 
(GO:0006941);structural constituent of 
muscle (GO:0008307);structural 
molecule activity 
(GO:0005198);transferase activity 
(GO:0016740) 
-7.91 CSRP3 cysteine and glycine-rich 
protein 3 (cardiac LIM 
protein) 
None 
-7.66 MB myoglobin electron transporter activity 
(GO:0005489);globin 
(GO:0001524);oxygen transport 
(GO:0015671);oxygen transporter 
activity (GO:0005344);transport 
(GO:0006810) 
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-7.46 ENO3 enolase 3, (beta, muscle) glycolysis (GO:0006096);lyase activity 
(GO:0016829);magnesium ion binding 
(GO:0000287);phosphopyruvate 
hydratase activity (GO:0004634) 
-7.32 NTRK2 neurotrophic tyrosine 
kinase, receptor, type 2 
ATP binding (GO:0005524);kinase 
activity (GO:0016301);neurogenesis 
(GO:0007399);neurotrophin TRKB 
receptor activity 
(GO:0005015);neurotrophin binding 
(GO:0043121);protein amino acid 
phosphorylation (GO:0006468);receptor 
activity (GO:0004872);transferase 
activity (GO:0016740);transmembrane 
receptor protein tyrosine kinase activity 
(GO:0004714);transmembrane receptor 
protein tyrosine kinase signaling 
pathway (GO:0007169) 
-7.28 MYL2 myosin, light polypeptide 
2, regulatory, cardiac, 
slow 
calcium ion binding 
(GO:0005509);muscle development 
(GO:0007517);structural constituent of 
muscle (GO:0008307) 
-7.27 TF Transferring ferric iron binding (GO:0008199);iron 
ion binding (GO:0005506);iron ion 
homeostasis (GO:0006879);iron ion 
transport (GO:0006826);transport 
(GO:0006810) 
-7.16 ACSL1 acyl-CoA synthetase long-
chain family member 1 
digestion (GO:0007586);fatty acid 
metabolism (GO:0006631);ligase 
activity (GO:0016874);long-chain-fatty-
acid-CoA ligase activity 
(GO:0004467);magnesium ion binding 
(GO:0000287);metabolism 
(GO:0008152) 
-7.10 MYBPC1 myosin binding protein C, 
slow type 
actin binding (GO:0003779);cell 
adhesion (GO:0007155);cell adhesion 
molecule activity (GO:0005194);muscle 
development (GO:0007517);protein 
binding (GO:0005515);striated muscle 
contraction (GO:0006941);structural 
constituent of muscle (GO:0008307) 
-7.07 S100A2 S100 calcium binding 
protein A2 
biological_process unknown 
(GO:0000004);calcium ion binding 
(GO:0005509) 
-7.07 PYGM phosphorylase, glycogen; 
muscle (McArdle 
syndrome, glycogen 
storage disease type V) 
amino acid metabolism 
(GO:0006520);carbohydrate metabolism 
(GO:0005975);glycogen metabolism 
(GO:0005977);glycogen phosphorylase 
activity (GO:0008184);transferase 
activity, transferring glycosyl groups 
(GO:0016757) 
-6.99 ACTN2 actinin, alpha 2 actin binding (GO:0003779);calcium ion 
binding (GO:0005509);protein binding 
(GO:0005515);structural constituent of 
muscle (GO:0008307) 
-6.76 MYBPC2 myosin binding protein C, 
fast type 
actin binding (GO:0003779);cell 
adhesion (GO:0007155);cell adhesion 
molecule activity (GO:0005194);muscle 
development (GO:0007517);protein 
binding (GO:0005515);striated muscle 
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contraction (GO:0006941);structural 
constituent of muscle (GO:0008307) 
-6.71 UCP2 uncoupling protein 2 
(mitochondrial, proton 
carrier) 
binding (GO:0005488);mitochondrial 
transport (GO:0006839);proton transport 
(GO:0015992);small molecule transport 
(GO:0006832);transport 
(GO:0006810);transporter activity 
(GO:0005215);uncoupling protein 
activity (GO:0015302) 
-6.63 NEB nebulin actin binding (GO:0003779);muscle 
development (GO:0007517);regulation 
of actin filament length 
(GO:0030832);somatic muscle 
development (GO:0007525);structural 
constituent of muscle (GO:0008307) 
-6.60 IDH2 isocitrate dehydrogenase 2 
(NADP+), mitochondrial 
carbohydrate metabolism 
(GO:0005975);glyoxylate cycle 
(GO:0006097);isocitrate dehydrogenase 
(NADP+) activity (GO:0004450);main 
pathways of carbohydrate metabolism 
(GO:0006092);metabolism 
(GO:0008152);oxidoreductase activity 
(GO:0016491);tricarboxylic acid cycle 
(GO:0006099) 
-6.47 CSTA cystatin A (stefin A) cysteine protease inhibitor activity 
(GO:0004869);endopeptidase inhibitor 
activity (GO:0004866) 
-6.45 MYH2 myosin, heavy polypeptide 
2, skeletal muscle, adult 
ATP binding (GO:0005524);actin 
binding (GO:0003779);calmodulin 
binding (GO:0005516);microfilament 
motor activity (GO:0000146);motor 
activity (GO:0003774);muscle 
contraction (GO:0006936);muscle 
development (GO:0007517);muscle 
motor activity (GO:0003776);protein 
amino acid alkylation 
(GO:0008213);striated muscle 
contraction (GO:0006941) 
-6.42 KRT4 keratin 4 cytoskeleton organization and 
biogenesis (GO:0007010);structural 
constituent of cytoskeleton 
(GO:0005200);structural molecule 
activity (GO:0005198) 
-6.40 CLIC6 chloride intracellular 
channel 6 
chloride transport (GO:0006821);ion 
transport (GO:0006811);voltage-gated 
chloride channel activity (GO:0005247) 
-6.27 SPRR1A small proline-rich protein 
1A 
structural molecule activity 
(GO:0005198) 
-6.25 TNNI2 troponin I, skeletal, fast actin binding (GO:0003779);muscle 
development (GO:0007517) 
-6.22 TNNI1 troponin I, skeletal, slow actin binding (GO:0003779);muscle 
development 
(GO:0007517);tropomyosin binding 
(GO:0005523) 
-6.17 LDB3 LIM domain binding 3 electron transport 
(GO:0006118);electron transporter 
activity (GO:0005489);protein binding 
(GO:0005515) 
-6.14 CRYAB crystallin, alpha B chaperone activity 
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(GO:0003754);muscle contraction 
(GO:0006936);protein folding 
(GO:0006457);structural constituent of 
eye lens (GO:0005212);visual 
perception (GO:0007601) 
-6.12 HFL1 H factor (complement)-
like 1 
plasma protein (GO:0005209) 
-6.15 S100A1 S100 calcium binding 
protein A1 
calcium ion binding (GO:0005509);cell 
communication 
(GO:0007154);intracellular signaling 
cascade (GO:0007242);neurogenesis 
(GO:0007399);protein binding 
(GO:0005515);zinc ion binding 
(GO:0008270) 
-6.09 HSPB8 heat shock 22kDa protein 
8 
biological_process unknown 
(GO:0000004);heat shock protein 
activity (GO:0003773);protein 
serine/threonine kinase activity 
(GO:0004674);transferase activity 
(GO:0016740) 
-5.93 PPFIBP2 PTPRF interacting protein, 
binding protein 2 (liprin 
beta 2) 
None 
-5.88 GHR growth hormone receptor endocytosis (GO:0006897);growth 
hormone receptor activity 
(GO:0004903);growth pattern 
(GO:0007150);receptor activity 
(GO:0004872);skeletal development 
(GO:0001501) 
-5.85 ACSL1 acyl-CoA synthetase long-
chain family member 1 
digestion (GO:0007586);fatty acid 
metabolism (GO:0006631);ligase 
activity (GO:0016874);long-chain-fatty-
acid-CoA ligase activity 
(GO:0004467);magnesium ion binding 
(GO:0000287);metabolism 
(GO:0008152) 
-5.84 MGC42493 hypothetical protein 
MGC42493 
nucleic acid binding (GO:0003676);zinc 
ion binding (GO:0008270) 
-5.73 SCD stearoyl-CoA desaturase 
(delta-9-desaturase) 
fatty acid biosynthesis 
(GO:0006633);iron ion binding 
(GO:0005506);oxidoreductase activity 
(GO:0016491);stearoyl-CoA 9-
desaturase activity (GO:0004768) 
-5.67 hIAN2 human immune associated 
nucleotide 2 
GTP binding (GO:0005525) 
-5.65 PDE4DIP phosphodiesterase 4D 
interacting protein 
(myomegalin) 
None 
-5.63 HBA2 hemoglobin, alpha 2 oxygen transport (GO:0015671);oxygen 
transporter activity 
(GO:0005344);protein binding 
(GO:0005515);transport (GO:0006810) 
Table 5 – PC21 Tissue Partitioning and Ordering 
Partitioning and ordering of tissues into sets UP21 (n=8) and DOWN21 (n =20) sets 
found to have significant expression differences for H21 and L21 at test1Thresh=0.05.  
Tissues within groups are ordered by decreasing abs(mean(H21)-mean(L21)), which 
has the effect of placing the most significantly affected tissues at the top of each list. 
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The most significant tissues in UP21 are at the left of Figure 4, and the most 
significant conditions in DOWN21 are at the right of Figure 4. 
 
UP21 DOWN21 
Pancreas TONGUE 
Pancreas SkeletalMuscle 
PancreaticIslets TONGUE 
PancreaticIslets SkeletalMuscle 
bonemarrow Thyroid 
bonemarrow Heart 
BM-CD34+ Thyroid 
BM-CD34+ fetalThyroid 
 Heart 
 fetalThyroid 
 testis 
 721_B_lymphoblasts 
 testis 
 ADIPOCYTE 
 721_B_lymphoblasts 
 ADIPOCYTE 
 Thalamus 
 caudatenucleus 
 spinalcord 
 Prostate 
Table 6 - GNF human expression principal components having extreme gene 
sets enriched in GO categories 
Each of the GNF human expression PCEG sets, derived using an extremeThresh of 
0.00001, was tested for Gene Ontology (GO) statistical enrichment.  Terms that were 
enriched for a particular PC at 1% significance threshold are reported.  26 of the top 
42 principal components produced extreme gene lists having significant GO term 
enrichment.    
PCEG Set GO Description (p-value) 
01 low  GO:0006412 protein biosynthesis (4.51e-07) 
03 high GO:0005201 extracellular matrix structural constituent (1.43e-08) 
03 low  GO:0007399 neurogenesis (5.05e-09)  
GO:0007268 synaptic transmission (9.6e-09)  
GO:0007417 central nervous system development (1.31e-08)  
GO:0016820 hydrolase activity, acting on acid anhydrides, catalyzing 
transmembrane movement of substances (4.85e-07)  
04 low  GO:0005201 extracellular matrix structural constituent (5.82e-07) 
05 high GO:0007067 mitosis (3.43e-17)  
GO:0051301 cell division (4.45e-17)  
GO:0048015 phosphoinositide-mediated signaling (5.07e-13)  
GO:0007049 cell cycle (1.79e-09)  
GO:0006260 DNA replication (5.37e-08)  
GO:0004674 protein serine/threonine kinase activity (1.09e-07)  
GO:0005524 ATP binding (1.29e-07)  
GO:0005634 nucleus (1.93e-07)  
GO:0006468 protein amino acid phosphorylation (1.01e-06) 
05 low  GO:0045012 MHC class II receptor activity (8.59e-08)  
GO:0006968 cellular defense response (5.07e-07)  
GO:0006955 immune response (6.9e-07) 
07 high GO:0005201 extracellular matrix structural constituent (3.27e-20)  
GO:0005578 extracellular matrix (sensu Metazoa) (2.94e-15)  
GO:0005581 collagen (1.76e-13)  
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GO:0006817 phosphate transport (2.79e-12)  
GO:0007517 muscle development (8.27e-10)  
GO:0005518 collagen binding (1.1e-07)  
GO:0008201 heparin binding (8.6e-07)  
GO:0007155 cell adhesion (1.55e-06)  
GO:0005509 calcium ion binding (2.16e-06) 
08 high GO:0007283 spermatogenesis (3.91e-10) 
11 low  GO:0042742 defense response to bacteria (1.09e-06) 
13 high GO:0019884 antigen presentation, exogenous antigen (3.23e-16)  
GO:0019886 antigen processing, exogenous antigen via MHC class II (5.1e-16)  
GO:0045012 MHC class II receptor activity (5.1e-16)  
GO:0006955 immune response (1.28e-15) 
13 low  GO:0006955 immune response (9.9e-16)  
GO:0042110 T cell activation (1.15e-10)  
GO:0007166 cell surface receptor linked signal transduction (1.64e-10)  
GO:0004888 transmembrane receptor activity (1.25e-09)  
GO:0006968 cellular defense response (2.05e-07)  
GO:0019735 antimicrobial humoral response (sensu Vertebrata) (4.81e-07)  
GO:0005515 protein binding  (1.4e-06) 
14 low  GO:0005615 extracellular space (4.94e-24)  
GO:0005319 lipid transporter activity (5.77e-11)  
GO:0007596 blood coagulation (6.05e-11)  
GO:0006953 acute-phase response (1.47e-10)  
GO:0004867 serine-type endopeptidase inhibitor activity (6.14e-10)  
GO:0004263 chymotrypsin activity (4.83e-09)  
GO:0004295 trypsin activity (7.86e-09)  
GO:0006810 transport (1.71e-08)  
GO:0016042 lipid catabolism (6.48e-08)  
GO:0005576 extracellular region (8.91e-08)  
GO:0008201 heparin binding (1.05e-07)  
GO:0006508 proteolysis and peptidolysis (4e-07) 
GO:0006869 lipid transport (1.14e-06) 
15 high GO:0005200 structural constituent of cytoskeleton (3.17e-12)  
GO:0005882 intermediate filament (1.99e-10)  
GO:0008544 epidermis development (4.44e-10) 
GO:0007517 muscle development (9.24e-10) 
15 low  GO:0008201 heparin binding (1.71e-07)  
GO:0005201 extracellular matrix structural constituent (3.95e-07) 
16 low  GO:0005179 hormone activity (4e-10)  
GO:0005576 extracellular region (1.51e-07)  
GO:0007565 pregnancy (1.57e-07) 
17 high GO:0006955 immune response (6.06e-07) 
18 high GO:0005882 intermediate filament (1.47e-11)  
GO:0005200 structural constituent of cytoskeleton (5.67e-10)  
GO:0005615 extracellular space (2.74e-08)  
GO:0008544 epidermis development (1.75e-07)  
GO:0005319 lipid transporter activity (9.61e-07)  
GO:0005198 structural molecule activity (1.72e-06) 
19 high GO:0005200 structural constituent of cytoskeleton (2.05e-07) 
20 high GO:0005179 hormone activity (1.88e-08)  
21 low  GO:0007517 muscle development (7.01e-27)  
GO:0008307 structural constituent of muscle (4.15e-23)  
GO:0003779 actin binding (6.2e-14)  
GO:0006941 striated muscle contraction (5.69e-10)  
GO:0005859 muscle myosin (1.99e-08) 
22 high GO:0016042 lipid catabolism (9.41e-08)  
GO:0004263 chymotrypsin activity (1.94e-06) 
23 high GO:0019825 oxygen binding (1.9e-08)  
GO:0005344 oxygen transporter activity (2.67e-07)  
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GO:0015671 oxygen transport (3.8e-07) 
24 low  GO:0007517 muscle development (8.02e-15)  
GO:0008307 structural constituent of muscle (2.11e-12)  
GO:0003779 actin binding (3.61e-09)  
GO:0005319 lipid transporter actiGO:0005856 cytoskeleton (1e-06) 
26 high GO:0005576 extracellular region (3.7e-10)  
GO:0005319 lipid transporter activity (2.31e-08)  
GO:0006869 lipid transport (9.09e-08) 
26 low  GO:0008307 structural constituent of muscle (1.19e-08)  
GO:0005344 oxygen transporter activity (2.67e-07)  
GO:0015671 oxygen transport (3.8e-07)  
29 high GO:0005615 extracellular space (1.8e-06) 
32 low  GO:0005576 extracellular region (3.34e-15)  
GO:0005615 extracellular space (6.56e-07) 
GO:0005179 hormone activity (2.15e-06) 
35 low  GO:0007585 respiratory gaseous exchange (4e-09) 
39 high GO:0005576 extracellular region (2.35e-07) 
40 high GO:0005179 hormone activity (8.22e-08)  
GO:0005576 extracellular region (9.39e-07) 
42 high GO:0005179 hormone activity (8.22e-08)  
GO:0005576 extracellular region (9.39e-07) 
 
Table 7 – Diabetes dataset covariates identified as correlated with principal 
components 
Results of a search for covariates with value distributions having significant 
differences in either UPn vs. DOWNn , {UPn+FLATn} vs. DOWNn , or UPn vs. 
{FLATn+DOWNn} are shown below.  An “X” indicates the covariate’s values varied 
significantly in the corresponding principal component’s sample partitioning. 11 (out 
of 53) covariates were identified at a 1% significance level (minSetSize=5) in 10 of 
the first 20 principal components.  To investigate further, corresponding plots of 
covariate value distributions within sample partitions can be generated, such as the 
covariate plots for PC14 (see Figure 5).   
 Principal Component Number 
  
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
Cap_(mm2) 
  
X 
                                    
Cap__Type2b_(mean_n) 
                    
X 
                  
Centroid_(Using_34_ 
OXPHOS-CR_Genes)               X                         
Insulin_0 
                          
X 
            
Patient_# 
      
X 
                                
Type1_Min_Area_(um2) 
                
X 
                      
Type2a_(n) 
            
X 
                          
Type2a_Min_Area_(um2) 
                              
X 
        
Type2b_(%) 
                          
X 
            
Type2b_(n) 
    
X 
                                  
UQCRB_(209065_at) 
          
X 
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Additional files 
The supplemental files provided with this publication are only a representative set of 
those generated by the PCA interpretation software.  The complete collections of PCA 
interpretation results for both the GNF and diabetes datasets are provided as a 
supplement to this publication at [35]. 
 
Additional files 1 – pc07-outliers.txt  
Tab-delimited text file listing the high and low extreme genes for PC7, including PC7 
coefficient and additional GNF gene annotations: ProbeId, Name, Aliases, 
Description, Function and Protein Families. 
 
Additional files 2 – pc07-condition-groups.txt 
Tab-delimited text file listing the conditions that are up, flat and down for PC7, 
ordered by decreasing difference of means. 
 
Additional files 3 – pc07-eigenvector.jpg 
Trajectory plot of the PC7 eigenvector, or “eigen-condition”. 
 
Additional files 4 – pc07-outliers.png 
Scatter plot of gene probe expression levels projected onto PC6 vs. PC7 space.  The 
PC7 high and low extreme gene sets are highlighted in red and blue colors, 
respectively. 
 
Additional files 5 – pc07-outlier-trajectories-order-original.jpg 
Gene trajectory plots for PC7 high and low extreme gene sets with tissues in the order 
in which the original data were provided. 
 
Additional files 6 – pc07-outlier-trajectories-order-meandiff.jpg 
Gene trajectory plots for PC7 high and low extreme gene sets with tissues ordered by 
decreasing mean differences, and thus grouped by significance (up group at left, flat 
group in middle and low group at right).  
 




Figure 5
  
Additional files provided with this submission: 
Additional file 6 : pc07-outlier-trajectories-order-meandiff.png : 345Kb 
http://www.biomedcentral.com/imedia/8989861108532044/sup6.PNG 
Additional file 5 : pc07-outlier-trajectories-order-original.png : 371Kb 
http://www.biomedcentral.com/imedia/1217991919853201/sup5.PNG 
Additional file 4 : pc07-outliers.png : 77Kb 
http://www.biomedcentral.com/imedia/1968249682853177/sup4.PNG 
Additional file 3 : pc07-eigenvector.png : 43Kb 
http://www.biomedcentral.com/imedia/2978944648532009/sup3.PNG 
Additional file 2 : pc07-condition-groups.txt : 3Kb 
http://www.biomedcentral.com/imedia/1452245562853200/sup2.TXT 
Additional file 1 : pc07-outliers.txt : 42Kb 
http://www.biomedcentral.com/imedia/1647557880853199/sup1.TXT 
